EA201391673A1 - Биотехнологический хондроитинсульфат, сульфатированный в положении 4 или 6 на его полисахаридной цепи, и способ его получения - Google Patents

Биотехнологический хондроитинсульфат, сульфатированный в положении 4 или 6 на его полисахаридной цепи, и способ его получения

Info

Publication number
EA201391673A1
EA201391673A1 EA201391673A EA201391673A EA201391673A1 EA 201391673 A1 EA201391673 A1 EA 201391673A1 EA 201391673 A EA201391673 A EA 201391673A EA 201391673 A EA201391673 A EA 201391673A EA 201391673 A1 EA201391673 A1 EA 201391673A1
Authority
EA
Eurasian Patent Office
Prior art keywords
sulfation
chondroitinsulphate
biotechnological
sulfated
preparation
Prior art date
Application number
EA201391673A
Other languages
English (en)
Other versions
EA023849B1 (ru
Inventor
Давиде Бьянки
Марко Валетти
Паола Бацца
Никколо Миралья
Эрманно Валоти
Original Assignee
Ньосис С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT000829A external-priority patent/ITMI20110829A1/it
Priority claimed from IT000136A external-priority patent/ITMI20120136A1/it
Application filed by Ньосис С.П.А. filed Critical Ньосис С.П.А.
Publication of EA201391673A1 publication Critical patent/EA201391673A1/ru
Publication of EA023849B1 publication Critical patent/EA023849B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0069—Chondroitin-4-sulfate, i.e. chondroitin sulfate A; Dermatan sulfate, i.e. chondroitin sulfate B or beta-heparin; Chondroitin-6-sulfate, i.e. chondroitin sulfate C; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Настоящее изобретение раскрывает способ производства хондроитинсульфата со средней молекулярной массой (Mw) 10-30 кДа посредством химического сульфатирования, исходя из основной цепи несульфатированного хондроитина, полученного, в свою очередь, посредством кислотного гидролиза капсульного полисахарида К4, полученного прямо из Е. coli штамма О5:K4:Н4 или непосредственно произведенного из генетически модифицированного штамма Е. coli. Сульфатирование N-ацетил-D-галактозаминового остатка в положении 4 или 6 имеет место одновременно в одной и той же полисахаридной цепи, имитируя характер сульфатирования, наблюдаемый в натуральном хондроитинсульфате, в отличие от сульфатирования, получаемого способами синтеза, описанными до настоящего времени.
EA201391673A 2011-05-12 2012-05-10 Биотехнологический хондроитинсульфат, сульфатированный в положении 4 или 6 на его полисахаридной цепи, и способ его получения EA023849B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT000829A ITMI20110829A1 (it) 2011-05-12 2011-05-12 Condroitin solfato biotecnologico solfatato in posizione 4 o 6 sulla stessa catena polisaccaridica e procedimento per la sua preparazione
IT000136A ITMI20120136A1 (it) 2012-02-02 2012-02-02 Condroitin solfato biotecnologico a basso peso molecolare solfatato in posizione 4 o 6 sulla stessa catena polisaccaridica dotato di attivita' antiinfiammatoria e antiartritica e procedimento per la sua preparazione
PCT/EP2012/058654 WO2012152872A1 (en) 2011-05-12 2012-05-10 "biotechnological sulphated chondroitin sulphate at position 4 or 6 on the same polysaccharide chain, and process for the preparation thereof"

Publications (2)

Publication Number Publication Date
EA201391673A1 true EA201391673A1 (ru) 2014-03-31
EA023849B1 EA023849B1 (ru) 2016-07-29

Family

ID=46208441

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201391673A EA023849B1 (ru) 2011-05-12 2012-05-10 Биотехнологический хондроитинсульфат, сульфатированный в положении 4 или 6 на его полисахаридной цепи, и способ его получения

Country Status (25)

Country Link
US (2) US20140315854A1 (ru)
EP (1) EP2707396B1 (ru)
JP (1) JP6205350B2 (ru)
KR (1) KR101883910B1 (ru)
CN (1) CN103582653B (ru)
AU (1) AU2012252415B2 (ru)
BR (1) BR112013027389B1 (ru)
CA (1) CA2835498C (ru)
CY (1) CY1121099T1 (ru)
DK (1) DK2707396T3 (ru)
EA (1) EA023849B1 (ru)
ES (1) ES2705734T3 (ru)
GE (1) GEP201606591B (ru)
HR (1) HRP20190183T1 (ru)
HU (1) HUE042378T2 (ru)
IL (1) IL229367A (ru)
LT (1) LT2707396T (ru)
MX (1) MX351660B (ru)
PL (1) PL2707396T3 (ru)
PT (1) PT2707396T (ru)
RS (1) RS58293B1 (ru)
SG (1) SG194898A1 (ru)
SI (1) SI2707396T1 (ru)
WO (1) WO2012152872A1 (ru)
ZA (1) ZA201308458B (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20130117A1 (it) 2013-01-25 2014-07-26 Gnosis Spa Composizioni comprendenti condroitin solfato, enzimi proteolitici e composti sulfidrilati capaci di migliorare la biodisponibilita' del condroitin solfato
CZ2014451A3 (cs) * 2014-06-30 2016-01-13 Contipro Pharma A.S. Protinádorová kompozice na bázi kyseliny hyaluronové a anorganických nanočástic, způsob její přípravy a použití
CN111662394B (zh) * 2019-03-05 2022-11-04 中国医学科学院药物研究所 硫酸软骨素多糖半合成制备方法和应用
IT202000013618A1 (it) 2020-06-08 2021-12-08 Vivatis Pharma Gmbh Processo di estrazione di un acido ialuronico da un fungo, un acido ialuronico di origine vegetale e suo uso
IT202000013633A1 (it) 2020-06-08 2021-12-08 Vivatis Pharma Gmbh Processo di estrazione di una condroitina solfato da un fungo, una condroitina solfato di origine vegetale e suo uso

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3405120A (en) * 1966-01-27 1968-10-08 Green Cross Corp Low molecular chondroitin sulfate and method for manufacturing the same
US4704356A (en) * 1984-03-27 1987-11-03 Rush-Presbyterian-St. Luke's Medical Center Method of diagnosing cartilage tissue abnormalities
JPS6144822A (ja) * 1984-08-09 1986-03-04 Seikagaku Kogyo Co Ltd コンドロイチン硫酸含有抗疲労剤
JPH0699485B2 (ja) * 1984-08-14 1994-12-07 生化学工業株式会社 合成コンドロイチン多硫酸の製造法
US5856174A (en) 1995-06-29 1999-01-05 Affymetrix, Inc. Integrated nucleic acid diagnostic device
JP4258856B2 (ja) * 1998-03-06 2009-04-30 ニプロ株式会社 抗癌性複合体
ITMI20012200A1 (it) * 2001-10-22 2003-04-22 Ibsa Inst Biochimique Sa Processo per la preparazione di condroitin solfati dal polisaccaride k4 e prodotti ottenuti
JP2003128705A (ja) * 2001-10-29 2003-05-08 Kyowa Technos:Kk 低分子キトサンおよびその製造方法
JP4317350B2 (ja) * 2002-06-12 2009-08-19 生化学工業株式会社 顆粒球マクロファージコロニー刺激因子分泌促進剤
US8455458B2 (en) * 2002-10-16 2013-06-04 Arthrodynamic Technologies, Animal Health Division, Inc. Composition and method for treating connective tissue damage
JP4567942B2 (ja) * 2002-12-27 2010-10-27 生化学工業株式会社 破骨細胞形成抑制剤
JP4914594B2 (ja) * 2005-09-29 2012-04-11 ユニテックフーズ株式会社 関節痛改善用食品組成物
CN1789287A (zh) * 2005-12-20 2006-06-21 山东大学 一种多硫酸化硫酸软骨素及其制备方法
US20100286085A1 (en) * 2007-10-01 2010-11-11 Seikagaku Corporation Novel chondroitin sulfate having decreased molecular weight and use thereof
US8394782B2 (en) * 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having increased longevity
WO2009149155A1 (en) * 2008-06-04 2009-12-10 Amano Enzyme Usa., Ltd. Microbial-derived chondroitin sulfate
JP5435538B2 (ja) * 2008-09-25 2014-03-05 国立大学法人鳥取大学 コンドロイチン硫酸の低分子化物の製造方法
IT1402871B1 (it) * 2010-11-11 2013-09-27 Ibsa Inst Biochimique Sa Processo per ottenere condroitina solfatata in posizione 4 o 6 dei residui di n-acetil-galattosammina

Also Published As

Publication number Publication date
RS58293B1 (sr) 2019-03-29
EP2707396B1 (en) 2018-11-14
CN103582653B (zh) 2016-08-17
BR112013027389A2 (pt) 2017-01-17
CA2835498C (en) 2019-06-25
US20140315854A1 (en) 2014-10-23
US20160108139A1 (en) 2016-04-21
BR112013027389B1 (pt) 2021-06-01
EA023849B1 (ru) 2016-07-29
AU2012252415B2 (en) 2016-11-24
HRP20190183T1 (hr) 2019-03-22
ZA201308458B (en) 2015-02-25
PT2707396T (pt) 2019-01-23
HUE042378T2 (hu) 2019-06-28
US9908947B2 (en) 2018-03-06
IL229367A (en) 2016-11-30
DK2707396T3 (en) 2019-01-28
CN103582653A (zh) 2014-02-12
KR20140034790A (ko) 2014-03-20
GEP201606591B (en) 2017-01-10
JP6205350B2 (ja) 2017-09-27
SG194898A1 (en) 2013-12-30
LT2707396T (lt) 2019-01-10
MX2013013181A (es) 2013-12-12
CY1121099T1 (el) 2019-12-11
AU2012252415A1 (en) 2013-11-28
PL2707396T3 (pl) 2019-04-30
ES2705734T3 (es) 2019-03-26
SI2707396T1 (sl) 2019-02-28
JP2014514424A (ja) 2014-06-19
MX351660B (es) 2017-10-23
KR101883910B1 (ko) 2018-08-01
EP2707396A1 (en) 2014-03-19
CA2835498A1 (en) 2012-11-15
NZ617564A (en) 2015-06-26
WO2012152872A1 (en) 2012-11-15
IL229367A0 (en) 2014-01-30

Similar Documents

Publication Publication Date Title
CY1121099T1 (el) Βιοτεχνολογικα θειωμενη θειικη χονδροϊτινη στη θεση 4 ή 6 στην ιδια αλυσιδα πολυσακχαριτη, και μεθοδος για την παρασκευη αυτης
TR201903066T4 (tr) E. colı'de enzimatik konjugasyonla rekombinant aşı üretimi.
EA201200516A1 (ru) Способ продуцирования молекул, содержащих специализированные гликановые структуры
AR064558A1 (es) Proceso para la modificacion de las propiedades termicas y de digestion de almidones de maiz y harinas de maiz
BR112012028444A2 (pt) produção de soluções de proteínas solúveis a partir de pulsos
MX2017005784A (es) Dextranos gelificantes enzimaticamente polimerizados.
BR112018011801A2 (pt) ?método de produção de composições, composição e produto ingerível?
BR112015013933A2 (pt) fermentação sequencial de hidrolisato e sólidos de uma hidrólise de ácido diluído de biomassa para produzir produtos de fermentação
UA103176C2 (ru) Растение с повышенными показателями урожайности и способ его получения
FI20105641L (fi) Uusi menetelmä mikroselluloosan valmistamiseksi
EA201790856A1 (ru) Новый сульфат декстрана
NZ591364A (en) Soluble canola protein isolate production from protein micellar mass
IN2014DN09832A (ru)
EA201190283A1 (ru) Мультивалентный адъювантный дисплей
MX360025B (es) Polvo biocompuesto natural preparado a partir de biomasa de pichia pastoris, metodo de preparacion y su uso como excipiente.
BR112017004231A2 (pt) processo para produzir um precipitado estável enriquecido em ficobiliproteínas
DK2794665T3 (da) Ikke-antikoagulative glycosaminoglycaner omfattende disaccharid-gentagelsesenhed og medicinsk anvendelse deraf
AR078882A1 (es) Conjugados glucosilados de molecula de motivo repetido
EP2543681A4 (en) METHOD FOR THE PRODUCTION OF CATIONULATED CELLULOSE AND METHOD FOR THE PRODUCTION OF CATIONIZED HYDROXYALKYL CELLULOSE
EA201500607A1 (ru) Способ получения гидролизата биомассы
WO2012175742A3 (en) Methods for the production of a cosmetic composition comprising leukolectin and uses thereof
MY161883A (en) Method for increasing plant biomass
AR060182A1 (es) Polisacaridos capsulares tipo 5 y tipo 8 de cepas s. aureus de sobreproduccion
UA114085C2 (xx) Біотехнологічний хондроїтинсульфат, сульфатований в положенні 4 або 6 на його полісахаридному ланцюзі, і спосіб його отримання
EA201590148A1 (ru) Генетически модифицированные микроорганизмы, способные продуцировать бета-глюканы, и способ получения бета-глюканов

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG TJ TM